Advances in natural killer cell therapies for breast cancer
Immunology & Cell Biology · 2023-09 · 101 (8) · 705-726
DOI: 10.1111/imcb.12658 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology & Cell Biology, online erschienen am 06.06.2023. Verfasst von Seyedeh Zahra Fotook Kiaei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 182 Literaturangaben.
Abstract (Originalsprache)
Breast cancer (BC) is the most common cause of cancer death in women. According to the American Cancer Society's yearly cancer statistics, BC constituted almost 15% of all the newly diagnosed cancer cases in 2022 for both sexes. Metastatic disease occurs in 30% of patients with BC. The currently available treatments fail to cure metastatic BC, and the average survival time for patients with metastatic BC is approximately 2 years. Developing a treatment method that terminates cancer stem cells without harming healthy cells is the primary objective of novel therapeutics. Adoptive cell therapy is a branch of cancer immunotherapy that utilizes the immune cells to attack cancer cells. Natural killer (NK) cells are an essential component of innate immunity and are critical in destroying tumor cells without prior stimulation with antigens. With the advent of chimeric antigen receptors (CARs), the autologous or allogeneic use of NK/CAR–NK cell therapy has raised new hopes for treating patients with cancer. Here, we describe recent developments in NK and CAR–NK cell immunotherapy, including the biology and function of NK cells, clinical trials, different sources of NK cells and their future perspectives on BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Periodontics, Faculty of Dentistry, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
- Hematology, Oncology and Stem Cell Transplantation Research Center (HORCSCT), Tehran University of Medical Sciences, Tehran, Iran.
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
- Laboratory Department, Buraimi Hospital, Buraimi, Oman.
Zitieren
APA
Kiaei, S. Z. F., Nouralishahi, A., Ghasemirad, M., Barkhordar, M., Ghaffari, S., Kheradjoo, H., Saleh, M., Mohammadzadehsaliani, S., & Molaeipour, Z. (2023). Advances in natural killer cell therapies for breast cancer. Immunology & Cell Biology, 101(8), 705-726. https://doi.org/10.1111/imcb.12658
Vancouver
Kiaei SZF, Nouralishahi A, Ghasemirad M, Barkhordar M, Ghaffari S, Kheradjoo H, et al. Advances in natural killer cell therapies for breast cancer. Immunology & Cell Biology. 2023;101(8):705-726. doi:10.1111/imcb.12658
BibTeX
@article{Kiaei2023,
author = {Kiaei, Seyedeh Zahra Fotook and Nouralishahi, Alireza and Ghasemirad, Mohammad and Barkhordar, Maryam and Ghaffari, Sasan and Kheradjoo, Hadis and Saleh, Mahshid and Mohammadzadehsaliani, Saman and Molaeipour, Zahra},
title = {Advances in natural killer cell therapies for breast cancer},
journal = {Immunology & Cell Biology},
year = {2023},
volume = {101},
number = {8},
pages = {705--726},
doi = {10.1111/imcb.12658}
}
EUVIMED